Stock 688192 DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Stock

Equities

688192

CNE1000055W8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-21 pm EDT 		5-day change 1st Jan Change
37.68 CNY +6.44% Intraday chart for Dizal (Jiangsu) Pharmaceutical Co., Ltd. -5.80% -21.25%
Apr. 07 U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations CI
Feb. 23 Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2023 91.29M 12.6M Sales 2024 * 490M 67.62M Capitalization 15.66B 2.16B
Net income 2023 -1.12B -155M Net income 2024 * -649M -89.57M EV / Sales 2023 214 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 32 x
P/E ratio 2023
-17.4 x
P/E ratio 2024 *
-24.2 x
Employees 424
Yield 2023 *
-
Yield 2024 *
-
Free-Float 18.48%
More Fundamentals * Assessed data

Chart Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Dizal (Jiangsu) Pharmaceutical Co., Ltd.

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations CI
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine CI
Dizal Pharmaceutical Co., Ltd.(SHSE:688192) added to Shanghai Stock Exchange Health Care Sector Index CI
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH CI
Dizal Pharma to Invest 700 Million Yuan in New Dermatology Venture MT
Dizal Pharma Presents Positive Results of Lung Cancer Drug MT
Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients CI
Chinese Drug Regulator Puts Dizal Pharma's Lymphoma Drug in Priority Review MT
Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL CI
Dizal Pharmaceutical Co., Ltd.(XSSC:688192) added to S&P Global BMI Index CI
Dizal Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL CI
Dizal (Jiangsu) Pharmaceutical's Anti-Lymphoma Medication Research Results Published in European Oncology Journal MT
Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology CI
Anova Enterprises, Inc. Partners with Dizal Pharmaceuticals to Accelerate Development of DZD9008 for Patients with Advanced or Metastatic NSCLC with EGFR Exon20 Insertion Mutation CI
More news

Quotes and Performance

1 day+6.44%
1 week-5.80%
Current month-16.25%
1 month-13.22%
3 months-0.45%
6 months+15.65%
Current year-21.25%
More quotes

Highs and lows

1 week
34.31
Extreme 34.31
38.35
1 month
34.31
Extreme 34.31
45.83
Current year
24.82
Extreme 24.82
48.83
1 year
24.82
Extreme 24.82
55.33
3 years
19.02
Extreme 19.02
56.12
5 years
19.02
Extreme 19.02
56.12
10 years
19.02
Extreme 19.02
56.12
More quotes

Managers and Directors - Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Xiao Lin Zhang CEO
 Chief Executive Officer 60 17-10-26
Wei Wen Dong CHM
 Chairman 38 18-05-31
Hong Bin Lu DFI
 Director of Finance/CFO 46 20-06-30
Members of the board TitleAgeSince
Simon Lü BRD
 Director/Board Member 56 17-09-30
Xue Gong Wang BRD
 Director/Board Member 52 20-09-06
Guan Shan Zhu BRD
 Director/Board Member 60 20-09-07
More insiders

Quotes

Date Price Change Volume
24-04-22 37.68 +6.44% 2,325,619
24-04-19 35.4 -4.71% 2,408,522
24-04-18 37.15 -0.67% 1,599,289
24-04-17 37.4 +0.51% 1,843,790
24-04-16 37.21 -6.97% 2,385,552

End-of-day quote Shanghai S.E., April 21, 2024

More quotes

Company Profile

Dizal Jiangsu Pharmaceutical Co Ltd is a China-based company mainly engaged in the exploration, research, development and commercialization of innovative biomedicine. The Company focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The Company is still in the R&D stage.
Sector
Biotechnology & Medical Research
Calendar
2024-04-25 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
37.68 CNY
Average target price
52.16 CNY
Spread / Average Target
+38.42%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. Stock Dizal (Jiangsu) Pharmaceutical Co., Ltd.
-21.25% 2.16B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.49% 96.73B
ARGENX SE Stock argenx SE
-0.38% 21.31B
BIONTECH SE Stock BioNTech SE
-16.61% 21.21B
GENMAB A/S Stock Genmab A/S
-5.20% 18.79B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.14% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-27.40% 13.68B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.44% 13.44B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.29% 10.98B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-21.79% 8.56B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 688192 Stock